Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aeglea BioTherapeutics, Merck Enter Clinical Collaboration | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Aeglea BioTherapeutics, Merck Enter Clinical Collaboration

To evaluate the combination of Aeglea’s AEB1102 with Merck’s KEYTRUDA for the treatment of Small Cell Lung Cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aeglea BioTherapeutics, Inc., a biotechnology company developing enzyme-based therapeutics to treat rare genetic diseases and cancer, has entered into a clinical collaboration agreement with Merck to evaluate the combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of patients with small cell lung cancer (SCLC).

“Earlier this year, we selected SCLC as one of the single agent expansion arms for our ongoing Phase I trial based on preclinical and biomarker data indicating that SCLC may be responsive to arginine depletion with pegzilarginase. In addition, our preclinical data demonstrated a synergistic effect of pegzilarginase in combination with checkpoint inhibitors,” said James Wooldridge, M.D., chief medical officer of Aeglea. “Given the emerging relevance of checkpoint inhibitors, such as KEYTRUDA in SCLC, this collaboration represents an exciting step forward for Aeglea as we investigate the potential of pegzilarginase to treat this devastating disease.”

The multicenter Phase 1/2 study will evaluate overall response rate in patients with extensive disease SCLC who have relapsed or progressed after receiving platinum-based chemotherapy. Enrollment is expected to begin 1Q18. Additional details of the collaboration were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics